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Abstract
With a prevalence of 15%, migraine is the most common neurological disorder and among the most disabling diseases, taking
into account years lived with disability. Current oral medications for migraine show variable effects and are frequently associated
with intolerable side effects, leading to the dissatisfaction of both patients and doctors. Injectable therapeutics, which include
calcitonin gene–related peptide–targeting monoclonal antibodies and botulinum neurotoxin A (BoNT/A), provide a new para-
digm for treatment of chronic migraine but are effective only in approximately 50% of subjects. Here, we investigated a novel
engineered botulinum molecule with markedly reduced muscle paralyzing properties which could be beneficial for the treatment
of migraine. This stapled botulinum molecule with duplicated binding domain—binary toxin-AA (BiTox/AA)—cleaves
synaptosomal-associated protein 25 with a similar efficacy to BoNT/A in neurons; however, the paralyzing effect of BiTox/
AA was 100 times less when compared to native BoNT/A following muscle injection. The performance of BiTox/AA was
evaluated in cellular and animal models of migraine. BiTox/AA inhibited electrical nerve fiber activity in rat meningeal prep-
arations while, in the trigeminovascular model, BiTox/AA raised electrical and mechanical stimulation thresholds in Aδ- and C-
fiber nociceptors. In the rat glyceryl trinitrate (GTN) model, BiTox/AA proved effective in inhibiting GTN-induced hyperalgesia
in the orofacial formalin test. We conclude that the engineered botulinum molecule provides a useful prototype for designing
advanced future therapeutics for an improved efficacy in the treatment of migraine.
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Introduction
Migraine [1] is a disabling and undertreated disorder, affecting
~ 15% of the general population [2, 3], with a significant fi-
nancial burden for many countries [4, 5]. Studies in animal
models have uncovered several brain networks that are in-
volved in migraine pathophysiology, including the hypothal-
amus [6–9], the occipital cortex [7, 10–13], and the brainstem
[7, 14, 15]. Although it remains unclear which molecular
events initiate migraine attacks, there is a general agreement
that a successful treatment strategy will involve inhibition of
the peripheral trigeminal fibers innervating pain-producing
extracranial and intracranial structures.
A number of unspecific oral preventive medications are
available for patients with frequent or chronic migraine [16].
However, their side effects, need for daily intake, and variable
responses lead to dissatisfaction of both patients and the
treating consultants. In the last decade, injections of botulinum
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neurotoxin A (BoNT/A) gained FDA approval for preventive
treatment of chronic migraine (Botox, Allergan Inc., Irvine,
CA) [17–19], i.e., migraine occurring on at least 15 days/
month for more than 3 months [1]. Clinical studies demon-
strated that a series of Botox injections around the scalp lead to
a therapeutic improvement quantifiable as a ≥ 50% reduction
of headache days in about 50% of patients with chronic mi-
graine [20–23]. The clinical efficacy and minimally invasive
injections every 3 months have made BoNT/A an important
treatment option for patients with chronic migraine.
The precise molecular events that are affected by BoNT/A
in reducing migraine symptoms are not fully understood;
however, it is generally agreed that, in the treatment of mi-
graine, inhibition of the peripheral trigeminal fibers is of piv-
otal importance. BoNT/A is known as a strong paralyzing
substance, and therefore, its efficacy in the treatment of chron-
ic migraine is hampered by the dose-limiting concern about
muscle paralysis that occurs even at low nanogram doses [24].
BoNT/A cleaves its specific neuronal target—synaptosomal-
associated protein 25 (SNAP-25), a member of the SNARE
(soluble N-ethylmaleimide–sensitive factor attachment pro-
tein receptor) family of proteins, preventing the correct assem-
bly of the SNARE complex which leads to a potent blockade
of neurotransmitter and neuropeptide release. At the neuro-
muscular junction, BoNT/A-induced cleavage of SNAP-25
inhibits the release of acetylcholine from the nerve endings,
resulting in muscle paralysis [25]. Similarly, by cleaving
SNAP-25, BoNT/A can interfere with sensory neuronal secre-
tion by blocking the presynaptic release of neuropeptides and
neurotransmitters [26–28]. In animal models of migraine,
BoNT/A was shown to block the release of calcitonin gene–
related peptide (CGRP) and glutamate from trigeminal gan-
glion neurons [26–28]. In the trigeminovascular model of mi-
graine, BoNT/A was shown to block the mechanical activa-
tion and sensitization of C fibers [27, 29], as well as the chem-
ical activation of neurons upon stimulation of TRPV1 and
TRPA1 receptors [30]. However, the highly paralyzing nature
of native BoNT/A presents an obstacle to achieving a maxi-
mal therapeutic window in the treatment of chronic pain
conditions.
Development of anti-nociceptive drugs that can target neu-
rons involved in migraine and prevent this condition, with
fewer side effects, remains an unmet need. To improve the
efficacy and safety of BoNT/A, we introduce here a prototype
synthetic BoNT/A molecule with two receptor-binding do-
mains for strong binding to neurons. The new molecule,
named binary toxin-AA (BiTox/AA), is a larger molecule than
native BoNT/A, and this potentially could reduce its paralytic
activity due to reduced penetration into the tight neuromuscu-
lar junctions. BiTox/AA was investigated here in cell assays
and inmigraine animal models. Our data show that BiTox/AA
has similar efficacy in cleaving SNAP-25 as BoNT/A but acts
with a markedly lower muscle paralyzing effect.
Methods
Animals
All experiments described here meet the European
Community Council Directive of September 22, 2010
(2010/63/EEC). The corresponding ethics committees for the
use of animals in research in each of the countries and univer-
sities participating in this project also approved all experimen-
tal protocols. The IASP’s guidelines for pain research in ani-
mals were followed [31]. Experiments were carried out in
male Sprague-Dawley rats aged 6–10 weeks. All rats were
housed on a 12 h/12 h light/dark cycle with food and water
available ad libitum, at an ambient temperature of 22 °C.
BiTox/AA Production and Testing in Human
Neuroblastoma Cells
Preparation of BiTox/AA involved recombinant production of
3 structurally independent units: the receptor-binding domain
(HcA, BoNT/A 874–1296, UniProt K4LN57) independently
fused to synaptobrevin (rat syb2 25–84, UniProt P63045) or
syntaxin (rat syx 3, 195–253, UniProt Q08849) peptides and
the light-chain translocation domain (LHn) fused to SNAP-25
as described previously, similar to the preparation of BiTox/A
[32]. These recombinant proteins were expressed in bacteria,
purified, and then mixed to form BiTox/AA. Specifically,
proteins were expressed in a BL21 strain of Escherichia coli
as glutathione S-transferase C-terminal fusions. Proteins fused
to glutathione S-transferase were purified on Glutathione
Sepharose beads (GE Healthcare, Buckinghamshire, UK)
and eluted from beads in 20 mM HEPES, pH 7.3, and
100 mMNaCl (buffer A) using thrombin. Further purification
was achieved by gel filtration using a Superdex 200 10/200
GL column (GE Healthcare). The BiTox/AA was assembled
by mixing the three fusion proteins for 60 min at 20 °C, each
component at 1 μM concentration, in buffer A containing
0.4% octyl glucoside. After confirmation of the assembly by
SDS-PAGE and Coomassie staining, the protein was
aliquoted and stored at − 80 °C before functional experiments.
Cleaved SNAP-25 was analyzed by Western immunoblotting
of human SiMa neuroblastoma cells treated with BiTox/AA or
native BoNT/A for 3 days as previously described [32].
EMG Analysis of Rat Gastrocnemius Muscle
Eight- to ten-week-old rats were lightly anaesthetized with 2–
4% isoflurane. Stimulating needle electrodes (ELSTM2;
Biopac, Goleta, CA) were inserted perpendicularly into the
muscle approximately 0.5 cm from the fifth lumbar vertebrae
on either side. The anode was always placed distally and the
cathode placed proximally to the recording leg. A ground
electrode (EL452, Biopac) was placed in the base of the tail.
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A reference recording needle electrode (EL450, Biopac) was
placed over the tendon of the gastrocnemius muscle, and a
recording electrode was placed in the belly of the medial gas-
trocnemius muscle.
Compound muscle action potential (CMAP) measure-
ments were performed using a Biopac system with a bandpass
of 30–9999 Hz and 200× gain. A 0.2-ms pulse stimulation
was performed with a voltage stimulator (BSLSTMB).
Supramaximal stimulation was determined for each recording.
The amplitude of the CMAP waveform was then measured.
Eight recordings per leg were performed, and the largest three
recordings were averaged.
Baseline CMAP recordings were determined for the gas-
trocnemius of each hind limb. Groups of three rats were each
injected with 2 U, 6.3 U, 20 U, or 63 U BoNT/A (150 kDa,
Metabiologics; 1 U = 3.7 pg) or 1.5 ng, 5 ng, 16 ng, 50 ng, or
160 ng BiTox/AA (30 μl injection volume) subcutaneously
over the recording site of the left gastrocnemius muscle using
a BD Micro-Fine 0.5-ml insulin syringe immediately after
baseline recording. CMAPs were then recorded from both
gastrocnemius muscles again on days 1, 2, 3, and 7, and the
fold change in CMAP at each time point was calculated based
on the baseline CMAP recording for each rat individually.
Primary Culture of Trigeminal Neurons and
Immunocytochemistry
Trigeminal ganglia were dissected from 6–8-week-old rats
and digested for 1 h and 20 min at 37 °C with 1 mg/ml
Dispase II (D4693, 0.85 U/mg; Sigma, St. Louis, MO) and
0.6 mg/ml collagenase XI. Enzymes were dissolved in
155 mM NaCl (S/3160/60; Fisher Scientific, Loughborough,
UK), 4.8 mM HEPES sodium salt (H8651, Sigma), 5.6 mM
HEPES (B299-500; Fisher BioReagents, Loughborough,
UK), 1.5 mM KH2PO4 (P/5240/53, Fisher Scientific), and
10 mM D-(+)-glucose (G7528, Sigma). Digested ganglia were
triturated with a P1000 pipette, and the suspension was lay-
ered on top of 4 ml of 15% bovine serum albumin (A2153,
Sigma) in wash media then centrifuged at 110g for 5 min.
Wash media contained DMEM/F-12 with GlutaMax (31331;
Gibco, Loughborough, UK), 10% heat-inactivated horse se-
rum (26050, Gibco), and 1% penicillin–streptomycin (P0781,
Sigma). The supernatant was removed, and trigeminal gangli-
on neurons were resuspended in 5 ml of wash media and
centrifuged at 110 RCF for 5 min. The supernatant was re-
moved, and the neurons were resuspended in complete media,
containing Neurobasal A medium (10888, Gibco), 1% fetal
bovine serum (10500064, Gibco), 1% penicillin–streptomycin
(P0781, Sigma), 20 ng/ml NGFβ (SRP4304, Sigma), 1× B27
(17504-044, Gibco), 1% GlutaMax (35050-061, Gibco),
20 μM uridine (U3003, Sigma), and 20 μM 5′-fluoro-2′-
deoxyuridine (F0503, Sigma). Trigeminal neurons were plat-
ed on μClear 96-well plates (655090, Greiner, Kremsmünster,
Austria) which had been coated with 10 μg/ml laminin for at
least 2 h at 37 °C. Neurons were cultured for 7 days, with a
half-medium change at day 3. At DIV7, wells were treated
with 2 nM BiTox/AA or the vehicle control (n = 4 from two
animals, N = 2).
Immunocytochemistry of trigeminal ganglion neurons was
performed in 96-well plates (GreinerμClear). Trigeminal neu-
rons were washed once with ice-cold phosphate-buffered sa-
line then fixed with 4% paraformaldehyde for 10 min, all on
ice. Neurons were washed with PBS once at 20 °C then
permeabilized for 15 min with 0.1% Triton X-100 (BP151,
Fisher, Loughborough, UK). Wells were washed with PBS
twice, then blocking solution containing 2% fish skin gelatin
(G7765, Sigma), 0.1% Tween 20 (BP337, Fisher), and 2%
BSA (A2153, Sigma) in PBS was added for 1 h. Mouse
anti-beta III tubulin (MAB1195; R&D Systems, Abingdon,
UK) at 1:2000 dilution and rabbit anti-cleaved SNAP-25
(Davletov lab, raised against a synthesized peptide of
SNAP-25 190–197 (TRIDEANQ)) at 1:5000 dilution in
blocking solution were applied to the neurons for 1 h. Wells
were washed twice with PBS, then Alexa Fluor 488 goat anti-
mouse (A11029; Invitrogen, Carlsbad, CA) and Alexa Fluor
594 goat anti-rabbit (A11012, Invitrogen) were diluted at
1:2000 and DAPI was diluted at 1:10,000 in blocking solution
and applied to the trigeminal neurons for 45 min protected
from light. Wells were washed twice in PBS then imaged at
× 40 with a Leica DMIRB inverted epifluorescence micro-
scope and a Hamamatsu C4742-95 camera.
Electrophysiology in Hemiskull Preparations
Rat hemiskull preparation (n = 12 hemiskulls from 12 ani-
mals) for direct recording of action potentials from trigeminal
nerve ending was performed as described earlier [33, 34].
Briefly, rats were euthanized with carbon dioxide, and after
decapitation skin and flesh were removed, lower jaw was dis-
sected. Skull was cut sagittally, and brain was removed from
hemiskulls, while paying maximum attention to leave menin-
ges untouched. In the recording chamber, hemiskulls were
continuously perfused (6 ml/min) with oxygenated (5%
CO2/95% O2) isotonic artificial cerebrospinal fluid (aCSF)
(119 mM NaCl, 30 mM NaHCO3, 11 mM glucose, 2.5 mM
KCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM NaH2PO4). Next,
through a small incision in the dura mater, the nervus spinosus
of the mandibular branch of the trigeminal nerve was picked
up with a recording glass electrode (~ 150 μm inner diameter,
resistance ~ 1 M when filled with aCSF). The same electrode
was used for recording of action potentials generated in distal
parts of transected nervus spinosus. Reference silver electrode
was dipped into the bath with hemiskull preparation. At the
beginning of each experiment, 10 min of spontaneous activity
was recorded (baseline/control). BiTox/AA was applied in
aCSF, and hemiskulls were superfused with isotonic aCSF
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for 20min (washout). Recordings were taken with a low-noise
digital amplifier (ISO 80; WPI Inc., Sarasota, FL) with the
following parameters: bandpass of 300 Hz–3 kHz and gain
of 10,000. All recorded signals were digitized at 125 kHz
using a NIPCI 6221 data acquisition (DA) board (National
Instruments, Austin, TX). WinEDR software (Strathclyde
University, Glasgow, UK) was used for signal visualization
during experiments. Spike clustering was performed as previ-
ously described [34]. In brief, prior to data analyses, experi-
mental recordings were filtered by the digital Chebyshev type
II filter. A 20-s-long spikeless interval at the beginning of each
experiment was used for calculating the baseline noise vari-
ance for spike detection and scaling to enable averaging of the
data across multiple experiments. The recording was consid-
ered to contain a spike when its amplitude was greater than 4
standard deviations of the baseline noise. Recording ampli-
tude was normalized by baseline noise and expressed in arbi-
trary units. For each spike, we calculated its amplitude and
temporal parameters of the positive and negative phases (rise
time, decay time, spike areas, and duration) [34]. Further,
spike analysis was performed using a custom-made program
written in MATLAB (MathWorks, Natick, MA).
Extracellular Single-Cell Recording from Trigeminal
Ganglia
BiTox/AA (20 ng) or saline (total volume, 100μl) was injected
in a blinded fashion in the periorbital area of lightly anaesthe-
tized rats under isoflurane (1–2%). Seven days later, rats were
anaesthetized with an intraperitoneal injection of 60 mg/kg
pentobarbital sodium (Merial, Harlow, UK), and general an-
aesthesia wasmaintainedwith continuous intravenous infusion
of pentobarbital (12–15 mg/kg/h). A tracheotomy was per-
formed to permit ventilation of the animal, and end-tidal ex-
pired CO2 was monitored and maintained between 3.5 and
4.5% (CapStar-100; CWE, Oxford, UK). The left femoral vein
and artery were cannulated to allow for constant intravenous
infusion of anaesthetic and monitoring of blood pressure, re-
spectively. Adequate anaesthesia was judged by the absence of
toe-pinch withdrawal and eye-blink reflexes and gross changes
in blood pressure. Core temperature was monitored and main-
tained near 37 °C using a homoeothermic blanket system (TC-
1000, CWE). The animal was fixed on a stereotaxic frame
(Kopf Instruments, Tujunga, CA). Craniotomies were per-
formed to expose the middle meningeal artery and to allow
access to the recording electrode. Extracellular activity from
single units in the trigeminal ganglia, accessed stereotaxically,
was recorded using a glass-insulated tungsten microelectrode
(Kation Scientific, Minneapolis, MN) with an impedance of ~
1 MΩ. Signals were amplified and filtered as previously de-
scribed [35]. The conditioned signal was digitized for storage
on a computer using a Micro 1401-3 with Spike2 software
(CED, London, UK). Evoked potential activation thresholds
of single first-order neurons (~ 3–5 neurons per animal) were
assessed following electrical stimulation of the middle menin-
geal artery (1–30 V), via a Grass S88 stimulator (Grass
Instrumentat ion, West Warwick, RI) to act ivate
trigeminovascular afferents. Evoked potentials represent an
all or nothing event, allowing assessment of the threshold of
action potential activation by ramping up the stimulating volt-
age, while keeping the pulse width constant (0.1 ms).
Mechanical activation threshold was assessed using von Frey
filaments of increasing force (up to 15 g) on the periorbital area
over the receptive field, until an action potential was recorded
on a live data recording system. All cells included in this study
responded to electrical stimulation with latencies consistent
with Aδ fibers (typically 7–10 ms) or C fibers (typically 15–
70 ms). Recordings were made from cell bodies and were
characterized by their unfiltered biphasic action potential mor-
phology [36]. Cells received a nociceptive-specific mechano-
receptor input from cutaneous receptive fields on the face. The
receptive fields were all ipsilateral and involved the ophthalmic
(first) division of the trigeminal nerve.
Orofacial Formalin Test
Eight-week-old rats (SD; Charles River, Calco, Como, Italy)
weighing 235–240 g (N = 5–10/group) were used in behavior-
al testing. Rats were housed in plastic boxes in groups of 2
with water and food available ad libitum at the centralized
animal facility of the University of Pavia, Italy. All procedures
were conducted in accordance with the European Convention
for Care and Use of Laboratory Animals, and the experimental
protocol was approved by the Italian Ministry of Health
(Document N°1032/2015-PR). BiTox/AA (10 ng) or vehicle
(saline; total volume, 25 μl) was injected into the right upper
lip of rats. Seven days after treatment, rats were injected with
glyceryl trinitrate (GTN) or its vehicle and tested at the
orofacial formalin test 4 h later. GTN (Bioindustria L.I.M.,
Novi Ligure, Italy) was prepared from a stock solution of
5 mg/1.5 ml dissolved in 27% alcohol and 73% propylene
glycol. The GTN solution was diluted in saline (0.9% NaCl)
to reach the final concentration of alcohol of about 6% and
that of propylene glycol of 16% and was administered intra-
peritoneally (i.p.) at a dose of 10 mg/kg. The GTN vehicle
(i.p.) contained saline, 6% alcohol, and 16% propylene glycol.
Before behavioral test, all rats were acclimatized to the test
chamber for 20–25 min. For the quantification of the
nocifensive behavior, we used off-line analysis of the videos
recorded by a camera located 50 cm from the observation box
to offer a clear view of the rat. The subcutaneous injection of
formalin (1.5%, 50 μl) was performed into the right upper lip.
Immediately after formalin injection, each animal was placed
into the observation box and its behavior recorded for a 45-
min period [37]. Face rubbing was measured by counting the
seconds the rat spent grooming the injected area with the
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ipsilateral forepaw or hindpaw during the first 6 min after
formalin administration for phase I, and then from min 12 to
min 45 for phase II. Researchers who performed the evalua-
tions were blind to treatments.
Statistical Analysis
For the comparison of BiTox/A and BiTox/AA in SiMa neuro-
blastoma cells, the differences between groups were analyzed by
two-way analysis of variance (ANOVA) followed by Sidak’s
multiple comparisons test. To compare the effect of BiTox/AA
on basal and 4-AP–induced spiking activity in the meningeal
afferents, we used unpaired t test. For the behavioral response
following the GTN–orofacial formalin test, the differences be-
tween groups for each phase (GTN + vehicle vs GTN + BiTox/
AA) were analyzed by unpaired t test. Electrical and mechanical
action potential thresholds in the trigeminovascular activation
model of migraine were compared between groups with non-
parametric statistics using the Mann–Whitney U test.
Differences were considered to be significant when p is < 0.05.
Disclosures
The investigators have disclosed any potential conflicts to all
study participants in the Acknowledgments section of this
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Results
Synthesis of BiTox/AA and Its Functional Evaluation
In a recent study, we introduced a non-paralyzing BiTox/A
molecule which exhibited anti-nociceptive properties in the
range of 50–200 ng but was inferior to native BoNT/A in
the cleavage of SNAP-25 when assessed in neuronal cultures
[38]. Here, we used the same stapling system to prepare a
novel botulinum type A molecule carrying two binding do-
mains, unlike the previous BiTox/A. For protein linking, we
used three shortened SNARE helical polypeptides called
linkers 1, 2, and 3. These three linkers assemble spontaneous-
ly within 1 h into a highly stable helical bundle permitting on-
demand conjugation of proteins (Fig. 1a). We fused the bind-
ing domain of BoNT/A (HcA) separately to linkers 1 and 2,
while linker 3 was fused to the botulinum type A protease with
its translocation domain (commonly known as LHn). All three
fusion proteins were purified by affinity chromatography and
gel filtration on a Superdex 200 column. Mixing the two bind-
ing domains in the presence of LHn–linker 3 led to the forma-
tion of an SDS-resistant protein, named here BiTox/AA,
which exhibited higher molecular weight compared to native
BoNT/A due to the presence of the linking system and the
additional binding domain (Fig. 1b).
Next, we compared the cleavage of neuronal SNAP-25 by
BiTox/AA against native BoNT/A in human neuronal cultures
derived from SiMa neuroblastoma cells. Figure 2a shows that
dose dependence and the time-dependent rate of the cleavage
of SNAP-25 were very similar between BiTox/AA and native
BoNT/A. We previously found that BiTox/A with single
binding domain exhibited a significantly compromised para-
lytic activity which could be due to impeded penetration into
the tight neuromuscular junctions or into small synaptic ves-
icles operating in motor neurons. Therefore, we investigated
the properties of BiTox/AA after injection into the muscle,
Fig. 1 Synthesis of BiTox/AA. (a) Schematic showing the native BoNT/
A and formation of BiTox/AA from three individual fusion proteins. LHn
is the botulinum type A protease with its translocation domain, and HcA
is the binding domain of BoNT/A. The three linking peptides form an
irreversible complex (light blue). (b) Coomassie-stained SDS-PAGE gel
showing the formation of BiTox/AA after the 60-min assembly reaction.
The lane indicating 0 min demonstrates the initial protein amounts used in
the BiTox/AA assembly reaction. BiTox/AA exhibits higher molecular
weight compared to the native BoNT/A molecule. Excess amounts of
HcA with linkers 1 and 2 in the lane 60 min migrate at their original
positions. Molecular weight (MW) standards are shown on the right
Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo...
Fig. 2 Functional evaluation of BiTox/AA in neuronal cultures. (a,
Upper panel) example immunoblot of human SiMa neuroblastoma cells
treated with BiTox/AA or BoNT/A for 72 h using an anti-SNAP-25
antibody (n = 3). Note the downward molecular shift of SNAP-25 upon
the action of botulinum protease correlating with its increasing doses.
Positions of the intact and cleaved SNAP-25 are indicated. (a, Lower
panel) example immunoblot of SiMa neuroblastoma cells treated with
either 1 nM BiTox/AA or 1 nM BoNT/A for the indicated duration of
time using an anti-SNAP-25 antibody (n = 3). (b) Graph showing the
change in CMAP amplitude measured by EMG in rats 72 h after injection
with varying doses of BiTox/AA and BoNT/A, compared to the baseline
amplitude (left panel). Bar chart showing the dose difference in logarith-
mic scale required to achieve 50% reduction in CMAP values measured
24 h and 72 h post injection (right panel). (c) Example immunoblot
showing the specificity of the cSNAP-25 antibody to the cleaved end of
SNAP-25, as compared to antibody raised against the whole SNAP-25
protein. (d) Examples of fluorescent micrographs of cultured rat trigem-
inal neurons treated with either vehicle or BiTox/AA and co-
immunostained using the cSNAP-25 antibody and an anti-tubulin anti-
body. (e) BiTox/AA-cleaved SNAP-25 co-localizes with a subset of
CGRP neurons in rat trigeminal neuron culture
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using electromyography to determine changes in CMAP in
the gastrocnemius muscle of rats 24 h and 72 h post injection.
Figure 2b shows that BiTox/AA was around 100 times less
paralyzing than BoNT/A, based on the dose required to reduce
CMAP amplitude to 0.5 of the baseline levels (165 pg (24 h)
or 62 pg (72 h) for BoNT/A, 14.1 ng (24 h), or 9.3 ng (72 h)
for BiTox/AA).
Next, we investigated the action of BiTox/AA in rat tri-
geminal neurons in culture. At day 7 after dissection, the neu-
rons were treated for 24 h with 2 nM BiTox/AA or control
buffer and cleaved SNAP-25 was visualized using rabbit poly-
clonal antibody recognizing only the botulinum-cleaved end
of SNAP-25 (Fig. 2c). Figure 2d shows that cleaved SNAP-25
can be detected upon the addition of BiTox/AA in some tri-
geminal neurons, identified by co-staining with the general
neuronal marker beta-III tubulin. Importantly, we observed a
co-localization of BiTox/AA-cleaved SNAP-25 with CGRP
neurons (Fig. 2e). Together, we conclude that duplication of
the binding parts of BoNT/A with a simultaneous increase in
the molecular structure allows production of a lesser-
paralyzing agent that is still able to target sensory neurons
implicated in migraine biology.
Functional Assays in In Vitro Migraine Models
Migraine pathophysiology is believed to involve activation of
trigeminal fibers innervating the meninges [39]. Recordings of
the firing rate of trigeminal fibers in meningeal preparations
are an established method for assessing the efficacy of poten-
tial treatments in suppressing trigeminal fiber activation. The
effect of BiTox/AA on nociceptive firing in meningeal affer-
ents was evaluated in basal conditions and after activation of
nerve fibers with 4-AP. The latter was selected to robustly
unmask the activity in most of the fibers of the meningeal
nerve through an inhibitory action of 4-AP on voltage-gated
A-type and delayed-rectifier (DR) potassium channels (K(A)
and K(DR)) abundantly expressed in sensory neurons.
Figure 3a shows electrical activity of nerve fibers in hemiskull
preparations of rats in the absence and presence of 4-AP and
before (left) and after (right) exposure for 6 h to BiTox/AA at
a concentration of 10 nM. After application of 1 mM 4-AP to
an innervated area of meninges, the spiking activity was dra-
matically increased, eventually forming the very regular
pulse-like patterns of activity (Fig. 3a). The inhibitory effect
of BiTox/AA on 4-AP–activated nerve fiber activity was sig-
nificant for all time points as shown in Fig. 3b. Figure 3c
shows that the basal activity was 1357 ± 276 spikes during
20 min of observation (n = 6), whereas after BiTox/AA treat-
ment, the basal activity of nerve spikes was reduced to
579 ± 203 (n = 6, p = 0.046). After application of 4-AP, the
number of spikes in control experiments increased to
21,934 ± 4401 during a 20-min interval (n = 6, Fig. 3d). In
BiTox/AA-pretreated hemiskull preparations, the increase of
spiking activity after 4-AP was halved (10,530 ± 2560 spikes
during 20 min, n = 6, p = 0.049, Fig. 3d). In summary, these
results indicate that BiTox/AA reduces both spontaneous and
evoked activities in meningeal sensory afferents, previously
implicated as the site of migraine pain generation.
Trigeminovascular Model of Migraine
The trigeminovascular model of migraine is a useful in vivo
rodent model that utilizes direct stimulation of trigeminal neu-
rons through stimulation of trigeminal fiber endings innervat-
ing meningeal vasculature. This model is particularly useful in
the assessment of anti-migraine effects of established and po-
tential treatments [40]. To investigate the actions of BiTox/AA
in the trigeminovascularmodel ofmigraine, BiTox/AA (20 ng)
or saline was injected in a blinded and randomized fashion in
the periorbital region of the rats. Seven days later, primary
neurons with a biphasic action potential and a receptive field
corresponding to the periorbital region were recorded from the
trigeminal ganglia. First, the electrical stimulation threshold
required to induce an action potential from each neuron was
assessed following trigeminovascular activation with increas-
ing voltage [40]. Upon registration of an action potential, the
latency was calculated, and cells were classified as Aδ-fiber
(n = 73 in 14 animals) or C-fiber (n = 18 in 13 animals)
nociceptors. In this trigeminovascular activation model, both
Aδ- and C-fiber nociceptors recorded from BiTox/AA-treated
animals displayed a significantly higher electrical stimulation
threshold (median for Aδ fibers = 18 V; median for C
fibers = 20 V; Fig. 4a, b) compared to neurons recorded from
saline-treated animals (median for Aδ fibers = 12; median for
C fibers = 14.5 V; Aδ fibers: p < 0.001, r = − 0. 7; C fibers: p =
0.002, r = − 0.73) (Fig. 4a, b).
The same neurons were then tested for their mechanical
activation thresholds by applying von Frey hair with increas-
ing force on the receptive field found in the periorbital region.
A total of 48 Aδ fibers and 17 C fibers displayed an action
potential in response to mechanical stimulation. Activation
thresholds following mechanical stimulation were significant-
ly higher for both Aδ and C fibers recorded from animals
treated with BiTox/AA (median for Aδ fibers = 2.5 g; median
for C fibers = 7 g) compared to neurons recorded from saline-
treated animals (median for Aδ fibers = 0.07 g; median for C
fibers = 1.4 gr; Aδ fibers: p < 0.001, r = − 0. 72; C fibers: p =
0.001, r = − 0.81; Fig. 4c, d).
Effects of BiTox/AA in the GTN Migraine Model
Nitroglycerin, also known as GTN, is a nitric oxide donor that
can trigger migraine attacks in patients and is an established
model in testing anti-migraine drugs, both in humans and in
animals [41]. GTN injection in rodents is known to induce
sensitization that can be seen behaviorally as well as upon
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activation along the trigeminal system [40]. In agreement with
previous data [42, 43], in GTN-treated animals, the orofacial
formalin injection induced a significant increase in the
nocifensive behavior (face rubbing) as compared to rats treat-
ed with GTN vehicle (data not shown). Pretreatment with
BiTox/AA (10 ng) significantly reduced the duration of
GTN-induced nocifensive behavior during phase II when
compared to the vehicle group (Fig. 5a, b). Interestingly,
BiTox/AA also induced a significant reduction of face rub-
bing during phase I of the test (Fig. 5a).
Discussion
Novel nociceptive-specific treatments for migraine with better
efficacy and safety profiles compared to current medications
are an unmet need for patients. Safe preventive treatments for
chronic migraine are highly desirable, since nearly 50% of
patients consulting headache clinics have daily or near-daily
headaches [44, 45].
The precise molecular events that initiate migraine are not
fully understood; however, it is generally agreed that inhibition
of the peripheral trigeminal fibers is of pivotal importance in the
treatment of migraine. Stimulation of trigeminal fibers in
humans produces headache-like pain [46]. A key manifestation
of migraine is now considered to be the activation, or the per-
ception of activation, of these fibers [47]. The key pathway for
migraine pathophysiology is the trigeminovascular input from
trigeminal afferents innervating dural vessels via the trigeminal
ganglion to the trigeminocervical complex (TCC), which is the
key relay center for the transmission of nociceptive information
to higher brain centers where pain sensation is perceived.
Notably, sumatriptan and ergotamine do not cross the blood–
brain barrier [48, 49], neither do the newer developed mono-
clonal CGRP antibodies [50]; however, they successfully block
the trigeminal system in animal models of migraine and are
effective migraine treatments [43, 51, 52].
Here, we engineered and evaluated a novel molecule based
on the botulinum neurotoxin. BiTox/AA, a novel elongated
BoNT/A prototype molecule with double binding domains,
significantly suppressed the frequency of firing of trigeminal
f ibers in ex vivo semi-skull preparat ions. In the
trigeminovascular model of migraine where primary neurons
were recorded from the trigeminal ganglia of animals treated
with BiTox/AA or saline in the periorbital area, we observed
significantly higher activation thresholds upon electrical and
mechanical stimulation of both Aδ and C fibers in animals
treated with BiTox/AA. At the behavioral level, BiTox/AA
reduced the hyperalgesic response to orofacial formalin in
GTN-sensitized animal, an established behavioral model of
trigeminal hyperalgesia relevant for migraine pain [41]. We
observed that BiTox/AA significantly blocked GTN-induced
sensitization, as demonstrated by the marked reduction of the
nocifensive behavior during phases I and II of rats treated with
GTN and subsequently exposed to the orofacial formalin test.
Several reports showed that GTN induces spontaneous-like
Fig. 3 Inhibitory effect of BiTox/
AA on spiking activity in rat tri-
geminal meningeal preparation.
(a) Examples of basal and 4-AP–
induced spiking activities in the
meningeal afferents in control
conditions (left) and after 6 h of
exposure to BiTox/AA (right). (b)
The time course of 1 mM 4-AP
action in control condition and
after 6 h of exposure to BiTox/
AA (n = 6 for both conditions).
(c) Bar chart showing the number
of spontaneous spikes in a 20-min
recording in control conditions
(white) and after application of
BiTox/AA (gray, mean ± S.E.M.,
n = 6, p = 0.046, t test). (d) Bar
chart showing the number of
spikes during the 20-min action of
4-AP in control condition (white)
and after exposure to BiTox/AA
(gray, n = 6, p = 0.049, t test)
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headache attacks in migraine sufferers [53], possibly related to
sensitization phenomena, as suggested by neurophysiological
investigations in healthy subjects [54]. Peripheral and central
sensitizations are thus considered to be important components
of the maintenance of migraine [55–57]. Hence, a treatment
like BiTox/AA that suppresses trigeminovascular activation
and trigeminal nociceptive behavioral in the absence of the
muscle paralytic effects represents a promising preventive
treatment for migraine. Of note, BiTox/AA had 50 times bet-
ter efficacy in cleaving SNAP-25 in human neuronal cultures
compared to BiTox/A with the single botulinum binding do-
main [38] (data not shown) which likely allowed for the anal-
gesic effects in low nanogram range seen here. Future work
will need to establish the minimal doses of BiTox/AA re-
quired for therapeutic effects, maintaining the reduction of
migraine in the absence of side effects.
In vivo motor control testing revealed that BiTox/AA is
100 times less paralyzing than BoNT/A and does not induce
a generalized muscle weakness even at 100 ng dose which
would be a fatal dose of native BoNT/A in rats. This could
be explained by the increased size of BiTox/AA and thus
reduced ability to enter the tight neuromuscular junctions
(NMJs) and/or small synaptic vesicles operating in NMJs.
The absence of a paralyzing effect for BiTox/AA has a defi-
nite clinical relevance when considering that the muscle par-
alyzing effect of BoNT/A occurs even at very low doses [24].
The possibility to use BiTox/AA at doses comparably higher
than BoNT/A may provide additional clinical benefits to mi-
graine sufferers, for example by inducing a response in BoNT/
A non-responders or increasing the therapeutic effect in
BoNT/A partial responders. Given the expanding knowledge
we gained on migraine pathophysiology in recent years, the
muscle paralysis induced by BoNT/A is unlikely to contribute
towards its efficacy [58], making it an unwanted side effect
that potentially limits the efficacy of this treatment. BiTox/AA
has reduced toxicity, and hence, it is realistic to hypothesize
that a higher therapeutic efficacy could be achieved using
higher doses without increased safety concerns for patients.
However, a possible immunological response will need to be
considered carefully in such future translations.
Fig. 4 Analysis of the inhibitory effect of BiTox/AA on electrical and
mechanical activation thresholds of rat primary trigeminal neurons in the
trigeminovascular model of migraine. (a) Treatment with BiTox/AA sig-
nificantly increased the electrical stimulation threshold required to induce
an action potential recorded in vivo from trigeminal neurons with Aδ-
fiber (p < 0.001, Mann–Whitney U test) and C-fiber (p = 0.002, Mann–
Whitney U test) latencies, 7 days post treatment, compared to recordings
from trigeminal neurons in animals treated with saline. The whisker plots
show the medians with variability outside the upper and lower quartiles.
Dots indicate outliers. (b) Examples of traces of post-stimulus recordings
with subthreshold (0.1 ms, 11 V) and threshold (0.1 ms, 12 V) electrical
stimulations of the periorbital region (assessed as the minimum voltage
required to induce evoked action potentials). (c) Treatment with BiTox/
AA significantly increased the mechanical stimulation threshold required
to induce an action potential recorded in vivo from trigeminal neurons
with Aδ- and C-fiber latencies, 7 days post treatment, compared to the
mechanical threshold recorded from trigeminal neurons in animals treated
with saline. (d) Examples of traces of post-stimulus recordings with sub-
threshold (0.16, 0.4 g) and threshold (0.6 g) von Frey mechanical stimu-
lation of the periorbital region (assessed as the minimum von Frey force
required to induce an action potential when applied on the cell’s receptive
field)
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Our results show that BiTox/AA can cleave SNAP-25
similar to BoNT/A and at a similar rate in human SiMa
neuroblastoma cultures (Fig. 2a). BiTox/AA also cleaves
SNAP-25 in cultures of rat trigeminal ganglion neurons,
including a subset of CGRP-expressing neurons (Fig. 2e).
Although what triggers a migraine attack is yet to be un-
derstood, the trigeminal system is of pivotal importance in
sustaining head pain [47, 59, 60]. CGRP released from the
trigeminal system has been implicated in migraine patho-
physiology as its levels were found to be elevated during
migraine attacks, as well as in patients with chronic mi-
graine [61]. BoNT/A treatment in patients with chronic
migraine reduces interictal CGRP plasma levels [62, 63].
Sumatriptan, a well-established migraine treatment,
reverses CGRP increase in migraineurs [64], while CGRP
receptor antagonists are often effective in treating acute
attacks of migraine [65, 66]. BiTox/AA significantly in-
creased the threshold of mechanical and electrical stimula-
tion of both Aδ and C fibers (Fig. 4). Pertinently, BoNT/A
was suggested to attenuate the release of CGRP from
nociceptors and also to inhibit the release of glutamate
[27], the main excitatory neurotransmitter of trigeminal
fibers, and a major sensitizing molecule [67]. It will be
important to investigate in future experiments how
BiTox/AA could affect glutamatergic excitation during no-
ciceptive stimuli which was shown to be exacerbated in the
presence of CGRP [68].
Recently, a series of CGRP antagonists and monoclonal
antibodies against the CGRP system demonstrated thera-
peutic benefits in several controlled clinical trials conduct-
ed on large populations [43, 69]. However, the widespread
expression of CGRP and its receptors throughout the hu-
man body [70] could lead to unwanted side effects, includ-
ing a cardiovascular risk [71–73]. In contrast, BoNT/A
act ion is res t r ic ted to nociceptors in per ipheral
trigeminovascular neurons [29]. A possible distal effect
of BoNT/A has been proposed, as a result of its transport
to centrally projecting trigeminal terminals where it in-
hibits transmitter release, thus decreasing the activation of
second-order neurons in the trigeminocervical complex [74].
However, this distal action should not raise safety issues if
botulinum molecules only affect nociceptive pathways.
Together, a localized BoNT/A-based treatment, with a possi-
ble blockade of CGRP release [28] from trigeminal fibers near
the injection sites and potentially from centrally projected fi-
bers that are restricted to the nociceptive pathways, may rep-
resent a more efficient and safer treatment approach than the
systemic antibody-based CGRP blockade.
In conclusion, BiTox/AA has a potent SNAP-25 cleavage
activity but exhibits a reduced paralytic action. This novel
botulinum construct showed significant efficacy in animal
models in blocking activation of the trigeminal system and
in suppressing trigeminal hyperalgesia. This prototype mole-
cule therefore paves the way for a safe preventive treatment
for migraine with enhanced therapeutic effects as compared to
currently available options.
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Fig. 5 Effects of BiTox/AA in the orofacial formalin test in the glyceryl
trinitrate (GTN) animal model of migraine. Bar charts showing the effect
of BiTox/AA on total time (in seconds) spent on face rubbing in phases I
and II (a) and the time course of the face rubbing (b). Face rubbing was
evaluated by counting seconds animals spent grooming the injected area
with the ipsilateral forepaw or hindpaw in the periods 0–6 min (phase I)
and 12–45 min (phase II) after formalin injection. The observation time
was divided into 15 blocks of 3 min each (45 min total). In both phase I
and phase II, pretreatment with BiTox/AA significantly reduced the
GTN-induced increase in face rubbing time compared to pretreatment
with vehicle (GTN + vehicle) (*p < 0.05, **p < 0.01, unpaired t test)
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